CRYSTAL COLONE: Open Payments
NPI 1265742514 · NORCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,283 in 157 payments from 16 companies in 2025. Trend: 2023 $4,018 · 2024 $4,237 · 2025 $4,283
Food & beverage: $4,283
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 19 | $775 |
| Neurocrine BioSciences, Inc. | 19 | $619 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $590 |
| E.R. Squibb & Sons, L.L.C. | 19 | $475 |
| ABBVIE INC. | 14 | $407 |
| Vanda Pharmaceuticals Inc. | 22 | $405 |
| Alkermes, Inc. | 12 | $295 |
| Otsuka America Pharmaceutical, Inc. | 7 | $269 |
| Teva Pharmaceuticals USA, Inc. | 10 | $160 |
| Lundbeck LLC | 3 | $61 |
Products named: INGREZZA, CAPLYTA, COBENFY, VRAYLAR, FANAPT, INVEGA SUSTENNA, REXULTI, ARISTADA.
Industry payments across CA — which companies pay providers there.
